Pfizer, Inc. News

Do you have an interest in the products developed by Pfizer, Inc., or are you interested in the performance of the company? If you are you should register for the free Pfizer, Inc. news email from Wiser. Pfizer, Inc. is an American-based pharmaceutical company that researches, develops and manufactures medicines and vaccines. The products developed by the company are used all over the world. They include leading brands like Lipitor, Zithromax and Viagra. The company was founded in 1849 and today is one of the largest pharmaceutical companies in the world. Its current chairman and CEO is Ian Reed. Most analysts expect Pfizer, Inc. to expand through acquisitions over the coming years. The Wiser daily Pfizer, Inc. news email covers this news as well as analysis on the performance of the company, and details about its products. These articles come from the best sources around the web and are delivered in a comprehensive but simple to use format. Sign up today.

Recent Pfizer, Inc. News Coverage
 
Your Weekly Recommendations Tuesday, September 19, 2017
 
Recommended for you
Ad Com vote split on Pfizer's Sutent for certain kidney cancer patients
Seeking Alpha • Douglas W. House
Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT® in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery
BusinessWire
Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
BusinessWire
Rezoning of Williamsburg’s Pfizer site moves forward with City Planning approval
Curbed NY • Ameena Walker
Lyophilized Injectable Drugs Market, 2024 - Research and Markets
BusinessWire
Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts
BusinessWire
Global $2.85 Bn Chronic Idiopathic Constipation (CIC) Drugs Market to 2025 - Research and Markets
BusinessWire
Morning Break: Controlling HIV; War on Cholera; You'll Shoot Your Eye Out
MedPage Today • Medpage Today Staff
Global Diabetic Retinopathy Market Research Report 2017-2025 - Research and Markets
BusinessWire
4D Molecular Therapeutics Receives $3 Million Follow-On Funding from Cystic Fibrosis Foundation Therapeutics for Gene Therapy IND Candidate for Cystic Fibrosis
BusinessWire
 
Recommended for You
Pfizer, Inc.
Ad Com vote split on Pfizer's Sutent for certain kidney cancer patients
Seeking AlphaDouglas W. House
The FDA's Oncologic Drugs Advisory Committee voted 6-Yes and 6-No that the benefits of Pfizer's (PFE -0.2%) SUTENT (sunitinib malate) outweigh the risks for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following the removal of...
Share
Cancer, Pfizer, Inc.
Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT® in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery
BusinessWire
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drug Advisory Committee (ODAC) voted 6 in favor and 6 against the benefit-risk profile for SUTENT® (sunitinib) as adjuvant treatment of adult patients at high risk...
Share
Cancer, Infectious Disease
Transgene: First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
BusinessWire
STRASBOURG, France--(BUSINESS WIRE)--Transgene (Paris:TNG), a biotech company that designs and develops viral-based immunotherapies, today announces that the first patient has been treated at the Curie Institute, Paris, France, in a Phase 1b/2 clinical trial evaluating the combination of TG4001 with avelumab* as...
Share
Pfizer, Inc., Real Estate
Rezoning of Williamsburg’s Pfizer site moves forward with City Planning approval
Curbed NYAmeena Walker
It now moves on to the City Council for approval The redevelopment of the former Pfizer sites in Williamsburg is one step closer to becoming a reality; today, the City Planning Commission voted in favor of the project (the vote went 9-1),...
Share
Economic Policy, Epidemiology
Lyophilized Injectable Drugs Market, 2024 - Research and Markets
BusinessWire
DUBLIN--(BUSINESS WIRE)--The "Lyophilized Injectable Drugs to 2024" report has been added to Research and Markets' offering. The inherent instability of protein drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under...
Share
Pfizer, Inc.
Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts
BusinessWire
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 31, 2017. The purpose of the call is to provide an...
Share
GlaxoSmithKline plc, Pfizer, Inc.
Global $2.85 Bn Chronic Idiopathic Constipation (CIC) Drugs Market to 2025 - Research and Markets
BusinessWire
DUBLIN--(BUSINESS WIRE)--The "Global Chronic Idiopathic Constipation (CIC) Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025" report has been added to Research and Markets' offering. “Global Chronic Idiopathic Constipation (CIC) Drugs...
Share
Epidemiology, Health Care Costs
Morning Break: Controlling HIV; War on Cholera; You'll Shoot Your Eye Out
MedPage TodayMedpage Today Staff
Note that some links may require subscriptions. CDC says Lesotho can be added to the list -- now numbering five -- of African countries that are close to controlling their HIV epidemics. The latest on San Diego's hepatitis A outbreak: now at...
Share
Economic Policy, Pfizer, Inc.
Global Diabetic Retinopathy Market Research Report 2017-2025 - Research and Markets
BusinessWire
DUBLIN--(BUSINESS WIRE)--The "Global Diabetic Retinopathy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025" report has been added to Research and Markets' offering. “Global Diabetic Retinopathy Market Size, Market Share, Application Analysis,...
Share
Pfizer, Inc.
4D Molecular Therapeutics Receives $3 Million Follow-On Funding from Cystic Fibrosis Foundation Therapeutics for Gene Therapy IND Candidate for Cystic Fibrosis
BusinessWire
EMERYVILLE, Calif.--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a leader in adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced $3 million in additional funding from Cystic Fibrosis Foundation Therapeutics Inc., (CFFT) the non-profit drug discovery and development affiliate of the...
Share